India this week allowed Pfizer a patent on its pneumonia vaccine despite opposition by more than one civil society group. But in April, the Delhi High Court had shot down an application from Bayer for extension of patent of a kidney and liver cancer drug, creating space for local companies to produce the medicine at a cost 90 per cent less than the original. The two examples, with huge implications for health care for countries in the global “south”, are likely to figure at a key meeting of think tanks from these nations. The meeting begins on Thursday in New Delhi. ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?